24/7 Customer Support

Scoped Quote
Home/Consulting & Advisory/Healthcare Consulting
Healthcare & Life Sciences Consulting

From pipeline to market, with the evidence built in.

Research-led consulting for pharma, biotech, medtech, diagnostics, and healthcare investors: opportunity assessments, KOL and patient insight, pipeline intelligence, and market access landscaping across 50+ countries.

Request a Scoped QuotePlan an Engagement
or see everything the practice covers
Healthcare report librarya running start on your market
KOLs to patientscompliant, consented fieldwork
ISO 9001 · 27001MRSI member
Fixed quotebefore any work begins
INDICATION OPPORTUNITY ASSESSMENT
Rare Neurology · US and EU5Patient-based model · prepared for the portfolio committee
Opportunity: attractive, with two exploitable competitive gapsAssumptions exposed line by line · full evidence pack attached
Prevalent population 100%
Diagnosed 62%
Treated 41%
Addressable at launch 18%
Evidence: 24 KOL interviews+ payer landscape scan
Congress readout: day-2 brief delivered
30 KOLs mapped and ranked
Trusted for healthcare and life-sciences research by leading global companies
PfizerMerckMedtronicOtsuka PharmaceuticalOmronNagaseand many more
Who we serve

Built for the decisions your side of healthcare faces

For commercial, brand, and BD&L teams

  • Indication and opportunity assessments when the portfolio committee needs a defensible go/no-go
  • Pipeline and congress intelligence so competitor readouts never reach you through the news first
  • KOL mapping and patient journey research to ground launch planning in real stakeholders
  • BD&L target and asset screening on licensing-window timelines
From first-in-class to fast-follower, the work starts from our existing therapy-area coverage, not a blank page.

For medtech and diagnostics product and strategy teams

  • Procedure volume and adoption studies built bottom-up, not from top-down guesses
  • Hospital and purchasing dynamics research: who really decides, and on what criteria
  • Competitive landscaping across devices, diagnostics, and the digital layer moving into your space
  • Launch and market development support grounded in clinician and payer evidence
Device economics live or die on procedure counts and purchasing reality. We measure both.

For healthcare PE, VC, and corporate development

  • Asset and indication assessments on deal clocks, with the epidemiology exposed
  • Commercial due diligence support for healthcare targets, red-flag to full-scope
  • Pipeline and landscape work to pressure-test an investment thesis before capital moves
  • Post-deal market tracking so the thesis keeps getting tested after close
Deal-speed diligence runs through our advisory practice, with this team supplying the healthcare depth.

For digital health builders and their partners

  • Market sizing and segmentation for categories that didn't exist five years ago
  • Adoption and reimbursement environment research: what clinicians use, what payers cover
  • Partnership and channel landscaping across pharma, providers, and platforms
Where evidence is thin because the category is new, we build it with primary research.
The practice

Four pillars, honestly bounded

Every service names its deliverable and typical shape. Where a question needs capabilities we don't staff, we say so and route you right.

Commercial Strategy & Launch

Indication & opportunity assessmentsSized opportunity, landscape, go/no-go · typically 6 to 12 weeks
Launch readiness supportEvidence base, positioning inputs, launch tracking
BD&L target & asset screeningRanked shortlist with the evidence pack behind it
Entry, deal, and pricing depth runs through Consulting & Advisory

Pipeline, Portfolio & CI

Competitor pipeline monitoringBriefs and alerts across your named watchlist
Congress & conference coverageSame-week readouts from the meetings that matter
Asset & indication landscapingPhase-by-phase competitive map with implications
Standing programs run through Competitive Intelligence

Stakeholder Research

KOL identification & mappingRanked, evidence-based KOL map · typically 10 to 12 weeks
Patient journey & treatment flowQual plus quant journey with the leak points marked
Advisory board & HCP researchCompliant recruitment, moderation, and synthesis
Fieldwork and panels run through Custom Research & Surveys

Access Landscaping & Forecasting

Payer & reimbursement landscapingCountry-by-country access environment map
Pricing environment scansReference pricing and corridor context
Patient-based forecastingEpidemiology-driven model, assumptions exposed
Honest boundary: we deliver the landscape and evidence inputs. Cost-effectiveness models, value dossiers, and HTA submissions stay with your HEOR team or specialist partners, and we say so upfront.
Therapy area coverage

Where the library already runs deep

Click a therapy area to start a conversation about it. Coverage spans our published reports, trackers, and fieldwork experience.

OncologyReports & coverage
NeurologyReports & coverage
CardiologyReports & coverage
ImmunologyReports & coverage
Rare DiseasesReports & coverage
Infectious DiseasesReports & coverage
Diabetes & MetabolicReports & coverage
RespiratoryReports & coverage
OphthalmologyReports & coverage
Medtech & DiagnosticsReports & coverage
Plan an engagement

Two shortcuts before you brief us

Congress coverage calendar

Same-week readouts, competitor session tracking, and daily briefs from the meetings on your calendar.
ASCO Annual MeetingOncology · typically early June
ESMO CongressOncology · typically autumn
ASH Annual MeetingHematology · typically early December
AACR Annual MeetingCancer research · typically April
J.P. Morgan Healthcare ConferenceBiopharma strategy · typically January
ADA Scientific SessionsDiabetes · typically June

Indication opportunity checker

Tell us where you stand. We'll name the engagement that fits, and its honest shape.
Recommended engagement
Indication opportunity assessment · Project · typically 6 to 12 weeks

Scoped precisely on a call, with a fixed written quote before any work begins.

Sprint1 to 4 weeks

Red-flag reads, screens, single-congress coverage

Project4 to 12 weeks

Opportunity assessments, KOL maps, journey studies

RetainerOngoing

Pipeline watch, congress seasons, market tracking

How we quote: every engagement is scoped to the asset, therapy area, and evidence required, then priced in a fixed written quote before any work begins. The price does not move once agreed.

Compliance & trust

Healthcare research, handled like it matters

HCP and patient research carries obligations most industries never face. Here is what stands behind every healthcare engagement today.

Certified processes

ISO 9001:2015 quality management and ISO 27001 information security, independently certified.

Consented, GDPR-aligned fieldwork

Informed consent at recruitment and GDPR-aligned handling of respondent data, with NDAs standard.

Verified human respondents

Layered identity, fraud, and quality checks on every dataset, the same stack behind our custom research practice.

Industry membership

Member of the Market Research Society of India, operating from Chicago, Noida, and Tokyo.

On AI and synthetic patients: digital twins and synthetic personas are arriving fast in pharma insight work, and regulators are equally fast to ask how they were validated. Our position is simple: AI accelerates synthesis and analysis on top of verified human evidence. Findings that steer a launch, a deal, or a portfolio decision are built on real clinicians, payers, and patients, every time.
Decisions changed

What healthcare engagements look like in practice

Client names withheld under NDA, as is standard. More in our case study library.

BiotechOpportunity Assessment
An indication call the portfolio committee could defend
Before: two candidate indications, one development budget, and internal champions on both sides arguing from conviction.
The engagement: patient-based models for both indications, KOL interviews across three markets, and a competitive landscape with the gaps marked.
After: one indication showed a materially clearer treated-population path. The committee chose it with the assumptions exposed, not asserted.
Pharma BD&LTarget Screening · Sprint
A licensing shortlist inside the window
Before: a BD&L team tracking a therapy area informally, with a partnering window closing and no ranked view of available assets.
The engagement: a screening sprint across the asset universe: mechanism, phase, ownership, and deal signals, scored against the team's criteria.
After: a ranked shortlist with evidence packs reached the committee inside the window, and outreach started from the top of a defensible list.
MedtechAdoption Study
Procedure counts that reset a device forecast
Before: a device maker's regional forecast rested on top-down procedure estimates that field sales quietly disbelieved.
The engagement: bottom-up procedure volume research with clinicians and purchasing stakeholders across the priority regions.
After: the true addressable procedure base was materially different by region. Targets and territory plans were rebuilt on measured volumes.
Go deeper

The practices behind the practice

Competitive Intelligence

Standing pipeline watch, battlecards, and win/loss programs, run as a continuous capability.

Explore CI
Custom Research & Surveys

HCP and patient fieldwork, surveys, and interviews with human-verified respondents across 50+ countries.

Explore custom research
Consulting & Advisory

Market entry, M&A due diligence, and pricing engagements, with healthcare depth supplied by this practice.

Explore advisory
Before you brief us

Frequently asked questions

Are you healthcare specialists or a generalist research firm?
Healthcare is one of our largest practices, backed by a dedicated report library across major therapy areas, compliant HCP and patient fieldwork, and analysts who cover pharma, biotech, and medtech full time. And where a question needs capabilities we do not staff, such as health-economic modeling, we say so and deliver the evidence inputs instead. Specialists know their boundaries.
What does an engagement cost?
It depends on the asset, therapy area, geographies, and evidence required, which is why we do not publish flat rates. After a scoping call, you receive a fixed written quote before any work begins, and the price does not move once agreed.
Do you build HEOR models and value dossiers?
No, and we say so upfront rather than after the kickoff. We deliver payer and reimbursement landscaping, pricing environment scans, and the evidence base that health-economics teams build models and dossiers from. The modeling itself stays with your HEOR team or specialist partners, and our deliverables are built to hand off cleanly to them.
How is HCP and patient data handled?
Under informed consent captured at recruitment, GDPR-aligned handling of respondent data, ISO 27001 certified information security, and layered verification and fraud checks on every dataset. Engagements run under NDA as standard, and your findings stay yours.
How fast can you cover a congress or a deal?
Single-congress coverage is booked per event with daily briefs during the meeting. Screening sprints and red-flag reads run in 1 to 4 weeks. Full opportunity assessments typically take 6 to 12 weeks, and KOL mapping 10 to 12, because reaching the right clinicians properly takes the time it takes.
How does this relate to your other services?
This practice supplies the healthcare depth. Standing competitor programs run through Competitive Intelligence, fieldwork through Custom Research, and entry, deal, and pricing engagements through Consulting & Advisory. You brief one team either way.
Request a scoped quote

Tell us the asset and the decision

Describe the therapy area, where the asset stands, and the call you have to make. A senior healthcare analyst replies with a recommended approach, timeline, and fixed quote.

Senior healthcare analyst, not a sales sequence
Fixed written quote before any work begins
NDA before you share anything sensitive
Response within 1 business day

I’d like more information on the following consulting services:

Thank you. A senior analyst will reply with a recommended approach and fixed quote within one business day.
Scoped QuoteWhat We Do